Model inputs included HCV AB and RNA prevalence, test performance, linkage to care (LTC) rates, Tx initiation, clinic visit and testing costs
Abbott CEO: GLP-1 Concerns in Medtech Are Overblown Abbott CEO Robert Ford explains why hes not worried about the GLP-1 impact for medtech
Even though they are FDA approved, cost remains prohibitive for many patients. If the pill costs a lot less out-of-pocket than injected GLP-1 drugs, this may lead more people to choose it even though it may not produce as much weight loss, says Clifford Rosen, MD, a professor at Tufts University School of Medicine and the associate director of the MaineHealth Institute for Research in Scarborough
The decision to adjust dose based on heart rate should involve the overall clinical picture, not just one number in isolation
You can also refer to this article for more information
But that hasnt stopped her research lab from vigorously trying to understand it from a scientific point of view